Coherus Biosciences share price logo

Coherus Biosciences

NASDAQ: CHRS

$0.52

-0.06

(-9.91%)

Live

as on

Coherus Biosciences Stock Performance

as on November 13, 2026 at 2:51 am IST

  • Day's Low

    Day's High

    $0.51
    $0.57
    downward going graph

    2.82%

    Downside

    8.61%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $0.57
    $2.62
    downward going graph

    -8.80%

    Downside

    398.44%

    Upside

    downward going graph

Coherus Biosciences share price movements today

Previous Close
$0.58
Open
$0.56
Volume
2.0M
Market Cap
$99.0M
Day's Low - High
$0.51 - $0.57
52 Week Low - High
$0.57 - $2.62

Coherus Biosciences Historical Returns

1 Month Return
-43.45 %
3 Month Return
-50.21 %
1 Year Return
-57.17 %
3 Year Return
-63.36 %
5 Year Return
-96.87 %

Coherus Biosciences Stock Fundamentals & Key Indicators

Check Coherus Biosciences market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$99.0M

EPS (TTM)

-0.97

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

-0.76%

PE Ratio (TTM)

-0.66

Industry PE ratio

-2.55

PEG Ratio

-0.01

EBITDA

-142.5M

Revenue (TTM)

53.6M

Profit Margin

64.91%

Return On Equity TTM

-239.55%

Coherus Biosciences vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Coherus Biosciences with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Coherus Biosciences image
Coherus Biosciences
Buy$99.0M-96.87%-0.6664.91%0.00%
Moderna image
Moderna
Neutral$101.5B7.57%-35.4828.00%0.00%
BeOne Medicines image
BeOne Medicines
StrongBuy$48.4BNA68.2588.39%0.00%
Vertex Pharmaceuticals image
Vertex Pharmaceuticals
StrongBuy$138.9B192.08%34.9985.57%0.00%
Regeneron image
Regeneron
Buy$94.7B52.00%19.5185.77%0.40%

Stock Returns calculator for Coherus Biosciences Stock including INR - Dollar returns

The Coherus Biosciences stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Coherus Biosciences investment value today

Current value as on today

₹40,962

Returns

-₹59,038

(-59.04%)

Returns from Coherus Biosciences Stock

-₹61,412 (-61.41%)

Dollar Impact

₹2,374 (+2.37%)

Analyst Recommendation on Coherus Biosciences Stock

Based on 1 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 1 analysts, 100% of analysts recommend a 'BUY' rating for Coherus Biosciences. Average target price of $7.75

Coherus Biosciences Share Price Target

Get share price movements and forecasts by analysts on Coherus Biosciences.

What analysts predicted

93.23%UPSIDE

Target Price

$7.75

Current Price

$0.5248

Analyzed by

1 Analysts

High

$7

Target

$7.75

Low

$7

Coherus Biosciences target price $7.75, a slight upside of 93.23% compared to current price of $0.5248. According to 1 analysts rating.

Indian Investors' Interest in Coherus Biosciences Stock

Search interest for Coherus Biosciences Stock has increased by 35% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:35% versus previous 30 day period

Coherus Biosciences Quarterly Profit & Loss

All numbers in Millions USD

Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Total Revenue
64
70
54
7
10
11
12
12
14
14
Gross Profit
35
50
20
3
5
6
7
7
10
10
Operating Income
-20
-6
-42
-45
-45
-42
-45
-36
-32
-33
EBITDA
-6
-3
-44
-44
-41
-41
-43
-33
-30
-35
Interest Expense
5
5
5
2
2
2
2
2
2
2
Depreciation
1
1
1
1
1
0
0
0
0
0
Income Before Tax
-12
-10
-50
-47
-44
-44
-46
-36
-33
-38
Income Tax Expense
-
-
-
-
-
-
-
-
-
-
Net Income
-12
-10
-50
-56
-41
-35
-37
-37
-20
-39
Net Profit Margin
54.52%
70.69%
37.47%
51.32%
56.98%
59.49%
61.24%
61.86%
70.35%
65.36%

Coherus Biosciences Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
1
1
356
475
326
211
257
266
42
Gross Profit
-158
-1
338
438
268
140
98
149
24
Operating Income
-232
-204
107
156
-263
-256
-203
-111
-179
EBITDA
-225
-204
111
159
-260
-255
-193
60
-170
Interest Expense
9
9
17
21
22
32
40
27
9
Depreciation
3
3
3
2
3
3
3
5
3
Income Before Tax
-238
-209
92
135
-287
-291
-238
28
-183
Income Tax Expense
-
-
2
3
-
-
0
-
-
Net Income
-238
-209
89
132
-287
-291
-237
28
-170
Net Profit Margin
-10216.90%
-107.90%
95.20%
92.08%
82.36%
66.79%
38.19%
55.97%
57.94%

Coherus Biosciences Quarterly Cash Flow

All numbers in Millions USD

Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Net Income
-54
-10
-50
-56
297
-35
241
-37
-58
96
Operating Cash Flow
59
-62
28
-25
-46
-46
-19
-57
-119
23
Investing Cash Flow
27
0
0
-17
462
-67
-2
30
60
-7
Financing Cash Flow
-187
0
0
0
-281
0
8
53
53
12
Change in Cash
-100
-61
28
-43
134
-113
-14
26
-5
-29

Coherus Biosciences Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-238
-209
89
132
-287
-291
-237
28
168
Operating Cash Flow
-200
-159
28
154
-37
-241
-174
-20
-138
Investing Cash Flow
-4
-1
-12
-14
-138
-166
144
230
375
Financing Cash Flow
206
105
89
223
51
54
69
-186
-273
Change in Cash
1
-54
104
363
-123
-353
39
22
-37

Global Institutional Holdings in Coherus Biosciences

Check out the Institutions with significant holdings in Coherus Biosciences.

Funds
Holdings
BlackRock, Inc.
7.77%
Vanguard
4.08%
VANGUARD INDEX FUNDS
3.77%
iShares
3.32%
Delaware Group Equity Funds IV
1.75%
See all

Coherus Biosciences News & Key Events

  • img

    Today's Timeline - 10 November

    Tue, 10:21 PM

    -

    Guggenheim lowers Coherus price target to $8 from $10 while maintaining a Buy rating.

    Tue, 11:08 PM

    -

    Coherus reports Q3 EPS of 20c, below consensus of 21c, with revenue of $14.27M.

    Wed, 05:39 AM

    -

    Coherus earnings call highlights oncology growth, cash pressure, and plans for LOQTORZI market expansion.

Insights on Coherus Biosciences

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 831.1% return, outperforming this stock by 888.3%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Moderna, Inc. Common Stock has given 255.0% return, outperforming this stock by 318.4%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 14.30M → 14.27M (in $), with an average decrease of 0.2% per quarter

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 7 days, CHRS stock has moved down by -22.2%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, -20.63M → -39.33M (in $), with an average decrease of 90.7% per quarter

About Coherus Biosciences

Coherus Oncology, Inc. is a biopharmaceutical company primarily focused on the research, development, and commercialization of cancer immunotherapies across the United States. The company's commercialized products include several biosimilar therapies. These comprise UDENYCA, a long-acting granulocyte-colony stimulating factor biosimilar to Neulasta; YUSIMRY, an equivalent to Humira, prescribed for inflammatory conditions like rheumatoid arthritis, psoriasis, and Crohn's disease, which are characterized by heightened tumor necrosis factor (TNF) production; and CIMERLI, a Lucentis biosimilar aimed at treating specific ophthalmic disorders such as neovascular age-related macular degeneration, macular edema, and diabetic retinopathy. Beyond its commercial products, Coherus maintains a robust pipeline of investigational immunotherapies. This includes LOQTORZI, a novel, next-generation programmed death receptor-1 (PD-1) inhibitor; Casdozokitug, a recombinant human immunoglobulin G1 (IgG1) monoclonal antibody designed to target interleukin 27; CHS-114, a highly specific human afucosylated IgG1 monoclonal antibody targeting a chemokine receptor prevalent on Treg cells in the tumor microenvironment (TME); CHS-1000, an anti-ILT4 monoclonal antibody aimed at solid tumors; and GSK4381562, an antibody engineered to target CD112R on tumor cells. To support its endeavors, the company has forged several strategic alliances. These encompass a co-development and commercialization pact with Junshi Biosciences for toripalimab, as well as agreements with Surface and Adimab LLC. Its licensing portfolio includes arrangements with Bioeq AG, Genentech, Inc., Surface, and Vaccinex, Inc. Furthermore, Coherus has out-licensing agreements with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. Founded in 2010, the company currently operates as Coherus BioSciences, Inc., but is slated to officially rebrand as Coherus Oncology, Inc. in May 2025. Its headquarters are located in Redwood City, California.
OrganisationCoherus Biosciences
Headquarters333 Twin Dolphin Drive, Redwood City, CA, 94065, US
IndustryBiotechnology
CEODennis Lanfear

Key Management of Coherus Biosciences

Name

Title

Mr. Dennis M. Lanfear

Chairman, President & CEO

Ms. Rebecca Sunshine

Chief Human Resources Officer

Dr. Rosh Dias M.D., MRCP

Chief Medical Officer

Mr. Arvind Sood

Chief Strategy & Corporate Affairs Officer

Mr. Bryan J. McMichael

Chief Financial Officer

Ms. Carrie Graham

Vice President of Investor Relations & Advocacy

Mr. Andy Rittenberg

Chief Legal Officer

Mr. Michael Chen

Senior Vice President of Commercial Analytics & Trade

Dr. Theresa M. Lavallee Ph.D.

Chief Development Officer & Chairman of Scientific Advisory Board

Mr. Sameer Goregaoker

Chief Commercial Officer

FAQs

What is Coherus Biosciences share price today?

Coherus Biosciences share price today is $0.52 as on . Coherus Biosciences share today touched a day high of $0.57 and a low of $0.51.

What is the 52 week high and 52 week low for Coherus Biosciences share?

Coherus Biosciences share touched a 52 week high of $2.62 on and a 52 week low of $0.57 on . Coherus Biosciences stock price today i.e. is trending at $0.52,which is 79.94% down from its 52 week high and -8.09% up from its 52 week low.

What is Coherus Biosciences's market capitalisation today?

Coherus Biosciences market capitalisation is $0.00T as on .

How to invest in Coherus Biosciences Stock (CHRS) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Coherus Biosciences on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Coherus Biosciences Stock (CHRS) from India?

Indian investors can start investing in Coherus Biosciences (CHRS) shares with as little as ₹94.04000091552734 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹940.40 in Coherus Biosciences stock (as per the Rupee-Dollar exchange rate as on ). Based on Coherus Biosciences share’s latest price of $0.52 as on November 12, 2026 at 9:21 pm IST, you will get 19.0549 shares of Coherus Biosciences. Learn more about fractional shares .

What are the returns that Coherus Biosciences has given to Indian investors in the last 5 years?

Coherus Biosciences stock has given -96.87% share price returns and 26.34% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?